Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013

BOULDER, Colo., Jan. 29, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:   ARRY) will report financial results for the second quarter of fiscal 2013 on Monday, February 4, 2013, and will hold a conference call on Tuesday, February 5, 2013 at 9:00 a.m. eastern time to discuss these results.  Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

Conference Call Information


Tuesday, February 5, 2013


9:00 a.m. eastern time


(800) 447-0521


(847) 413-3238

Pass Code:    


Webcast & Conference Call Slides:

A replay of the call will be available as a webcast on

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company with significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.  Array-invented MEK162 will be tested in a Phase 3 trial in NRAS melanoma in the next several months as well as BRAF mutant melanoma later in 2013 (with Novartis).  Four other Array invented drugs are also approaching Phase 3 decisions by the end of calendar year 2013.  These include Array's wholly owned drugs, ARRY-614 and ARRY-520, and two additional partnered programs, selumetinib (with AstraZeneca) and danoprevir (with InterMune / Roche).  For more information on Array, please go to

SOURCE Array BioPharma Inc.


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.